NASDAQ:RYTM Rhythm Pharmaceuticals (RYTM) Stock Price, News & Analysis $64.01 +0.21 (+0.33%) Closing price 05/2/2025 04:00 PM EasternExtended Trading$62.76 -1.25 (-1.95%) As of 05/2/2025 05:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Rhythm Pharmaceuticals Stock (NASDAQ:RYTM) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Rhythm Pharmaceuticals alerts:Sign Up Key Stats Today's Range$63.89▼$66.0950-Day Range$46.95▼$65.2252-Week Range$35.17▼$68.58Volume475,184 shsAverage Volume548,111 shsMarket Capitalization$4.07 billionP/E RatioN/ADividend YieldN/APrice Target$74.92Consensus RatingBuy Company OverviewRhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.Read More… Rhythm Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks76th Percentile Overall ScoreRYTM MarketRank™: Rhythm Pharmaceuticals scored higher than 76% of companies evaluated by MarketBeat, and ranked 115th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingRhythm Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 13 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageRhythm Pharmaceuticals has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Rhythm Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Rhythm Pharmaceuticals are expected to grow in the coming year, from ($4.32) to ($2.58) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Rhythm Pharmaceuticals is -14.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Rhythm Pharmaceuticals is -14.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRhythm Pharmaceuticals has a P/B Ratio of 22.30. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Rhythm Pharmaceuticals' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted8.81% of the float of Rhythm Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverRhythm Pharmaceuticals has a short interest ratio ("days to cover") of 7.8.Change versus previous monthShort interest in Rhythm Pharmaceuticals has recently increased by 9.66%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldRhythm Pharmaceuticals does not currently pay a dividend.Dividend GrowthRhythm Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESG4.3 / 5Environmental Score-1.80 Percentage of Shares Shorted8.81% of the float of Rhythm Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverRhythm Pharmaceuticals has a short interest ratio ("days to cover") of 7.8.Change versus previous monthShort interest in Rhythm Pharmaceuticals has recently increased by 9.66%, indicating that investor sentiment is decreasing significantly. News and Social Media3.3 / 5News Sentiment1.00 News SentimentRhythm Pharmaceuticals has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.58 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 14 news articles for Rhythm Pharmaceuticals this week, compared to 7 articles on an average week.Search InterestOnly 1 people have searched for RYTM on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.MarketBeat Follows2 people have added Rhythm Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Rhythm Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $9,008,789.00 in company stock.Percentage Held by InsidersOnly 5.60% of the stock of Rhythm Pharmaceuticals is held by insiders.Read more about Rhythm Pharmaceuticals' insider trading history. Receive RYTM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Rhythm Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address RYTM Stock News HeadlinesRhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) EVP Sells $438,964.60 in StockMay 2 at 5:20 AM | insidertrades.comInsider Selling: Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) EVP Sells 17,750 Shares of StockApril 11, 2025 | insidertrades.comElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of collapse and built two of the most valuable companies in history. Now, he's sounding the alarm about America's $36 trillion debt time bomb that could destroy the fabric of our society.As head of the Department of Government Efficiency (DOGE) under President Trump, Musk is exposing just how bad things are...May 4, 2025 | American Hartford Gold (Ad)Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Receives $74.92 Average Target Price from AnalystsApril 26, 2025 | americanbankingnews.comRhythm Pharmaceuticals to Report First Quarter 2025 Financial Results on Wednesday, May 7, 2025April 23, 2025 | globenewswire.comRhythm Pharmaceuticals price target raised to $68 from $63 at BofAApril 11, 2025 | markets.businessinsider.comGuggenheim Sticks to Its Buy Rating for Rhythm Pharmaceuticals (RYTM)April 9, 2025 | markets.businessinsider.comRhythm jumps after late-stage trial win; BofA upgrades (update)April 8, 2025 | msn.comSee More Headlines RYTM Stock Analysis - Frequently Asked Questions How have RYTM shares performed this year? Rhythm Pharmaceuticals' stock was trading at $55.98 at the beginning of the year. Since then, RYTM stock has increased by 14.3% and is now trading at $64.01. View the best growth stocks for 2025 here. How were Rhythm Pharmaceuticals' earnings last quarter? Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) issued its earnings results on Wednesday, February, 26th. The company reported ($0.72) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.69) by $0.03. The company had revenue of $41.83 million for the quarter, compared to analyst estimates of $38.48 million. Rhythm Pharmaceuticals had a negative trailing twelve-month return on equity of 367.36% and a negative net margin of 230.07%. Read the conference call transcript. When did Rhythm Pharmaceuticals IPO? Rhythm Pharmaceuticals (RYTM) raised $100 million in an initial public offering (IPO) on Thursday, October 5th 2017. The company issued 6,700,000 shares at $14.00-$16.00 per share. Morgan Stanley, BofA Merrill Lynch and Cowen acted as the underwriters for the IPO and Needham was co-manager. Who are Rhythm Pharmaceuticals' major shareholders? Top institutional shareholders of Rhythm Pharmaceuticals include Bank of New York Mellon Corp (0.23%), Hennion & Walsh Asset Management Inc. (0.14%), Rhumbline Advisers (0.14%) and Harbor Capital Advisors Inc. (0.12%). Insiders that own company stock include David P Meeker, Hunter C Smith, Yann Mazabraud, Pamela J Cramer, Joseph Shulman, William T Roberts, Jennifer Kayden Lee, Jennifer Chien, Jennifer L Good, Lynn A Tetrault and Christopher Paul German. View institutional ownership trends. How do I buy shares of Rhythm Pharmaceuticals? Shares of RYTM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Rhythm Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Rhythm Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM), Netflix (NFLX), Tesla (TSLA) and Palo Alto Networks (PANW). Company Calendar Last Earnings2/26/2025Today5/03/2025Next Earnings (Estimated)5/07/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:RYTM CIK1649904 Webwww.rhythmtx.com Phone(857) 264-4280Fax857-264-4299Employees140Year FoundedN/APrice Target and Rating Average Stock Price Target$74.92 High Stock Price Target$92.00 Low Stock Price Target$63.00 Potential Upside/Downside+17.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage13 Analysts Profitability EPS (Most Recent Fiscal Year)($4.35) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-184,680,000.00 Net Margins-230.07% Pretax Margin-229.52% Return on Equity-367.36% Return on Assets-77.47% Debt Debt-to-Equity RatioN/A Current Ratio3.49 Quick Ratio3.34 Sales & Book Value Annual Sales$130.13 million Price / Sales31.28 Cash FlowN/A Price / Cash FlowN/A Book Value$2.87 per share Price / Book22.30Miscellaneous Outstanding Shares63,598,000Free Float58,015,000Market Cap$4.07 billion OptionableOptionable Beta2.36 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.Get This Free Report This page (NASDAQ:RYTM) was last updated on 5/4/2025 by MarketBeat.com Staff From Our PartnersThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | SponsoredIf you missed your chance with Tesla...Elon Musk is moments from launching a revolutionary technology some Silicon Valley insiders are calling "The F...Brownstone Research | SponsoredWill May start the next "Great Depression?"You probably haven't heard about this yet... But this could be the biggest wealth building opportunity of t...Behind the Markets | Sponsored🥾⛏️👷♂️ What I Learned From Numerous Mine Visits...Twenty years ago, I made a decision that changed my life. Instead of sitting behind a desk analyzing mining...Golden Portfolio | SponsoredThe Last Time This Happened, Americans Lost BillionsWall Street leaders just held a secret meeting in Las Vegas. What they discussed mirrors 2006 — and the warnin...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rhythm Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Rhythm Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.